Back to news

BioLineRx and Hemispherian Present Phase 1/2a Clinical Study and Pre-Clinical Updates, Including Brain PK/PD Data, at SNO 2026

PR Newswire•16/11/2026•07:00 ET
0

Key Highlights

  • ➤Fourth cohort initiated in GLIX1 Phase 1/2a study; no significant treatment-emergent adverse events observed
  • ➤Remaining GLIX1 cohorts will enroll window-of-opportunity patients for human brain-tumor exposure assessment
  • ➤GLIX1 eradicated tumors and prolonged survival in SNB19 glioblastoma CDX model
  • ➤GLIX1 inhibited growth in TMZ-resistant BN2276 PDX, while TMZ was ineffective
  • ➤Brain GLIX1 exposure increased with dose; tumor 5hmC rose dose-dependently in U87MG model

Expert Statements

Philip Serlin, Chief Executive Officer of BioLineRx

“The data presented at this year's SNO Annual Meeting further strengthen our belief in GLIX1 as a treatment for GBM. In parallel, our Phase 1/2a study is progressing very rapidly with no identified safety concerns, and we continue to look forward to results from the study in the first half of next year.”

Philip Serlin, Chief Executive Officer of BioLineRx

“We are particularly excited about the new window of opportunity cohorts being introduced into the study. Together with our new PK/PD data from the pre-clinical model, the data from these patients are expected to provide valuable information regarding exposure and activity in brain tumors.”

Adam Robertson, Ph.D., Chief Scientific Officer of Hemispherian AS

“The consistency and magnitude of GLIX1's antitumor activity across multiple GBM models are highly encouraging and further support the therapeutic rationale for its novel TET2-activating mechanism.”

Adam Robertson, Ph.D., Chief Scientific Officer of Hemispherian AS

“Particularly notable is the activity observed in the TMZ-resistant patient-derived model, as well as evidence of brain penetration and dose-dependent increases in tumor 5hmC, a marker of TET2 activity, in the orthotopic model, which strengthen the scientific rationale for advancing GLIX1 in glioblastoma.”

BioLineRx and Hemispherian Present Phase 1/2a Clinical Study and Pre-Clinical Updates, Including Brain PK/PD Data, at SNO 2026 PR Newswire

- Fourth cohort initiated in ongoing Phase 1/2a study of GLIX1; remaining cohorts to include patients in window-of-opportunity setting -

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in